U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C40H48N2O6.2I
Molecular Weight 906.6279
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METOCURINE IODIDE

SMILES

[I-].[I-].COC1=CC2=C3C=C1OC4=C(OC)C=CC(C[C@@H]5C6=C(CC[N+]5(C)C)C=C(OC)C(OC)=C6OC7=CC=C(C[C@@H]3[N+](C)(C)CC2)C=C7)=C4

InChI

InChIKey=DIGFQJFCDPKEPF-OIUSMDOTSA-L
InChI=1S/C40H48N2O6.2HI/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H/q+2;;/p-2/t31-,32+;;/m0../s1

HIDE SMILES / InChI

Molecular Formula C40H48N2O6
Molecular Weight 652.8189
Charge 2
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 2 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula HI
Molecular Weight 127.91241
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Metocurine, also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant through the neuromuscular blockade. It antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. Patients chronically receiving anticonvulsants are relatively resistant to metocurine.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
METOCURINE IODIDE

Approved Use

Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. Metocurine Iodide is no longer available on the US market.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.05 μg/mL
0.3 mg/kg single, intravenous
dose: 0.3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METOCURINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.46 μg/mL
0.3 mg/kg single, intravenous
dose: 0.3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METOCURINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.4 h
0.3 mg/kg single, intravenous
dose: 0.3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METOCURINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6 h
0.3 mg/kg single, intravenous
dose: 0.3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METOCURINE serum
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010-12
Impact of anti-cancer drugs and other determinants on serum protein binding of morphine 6-glucuronide.
2010
Site selectivity of competitive antagonists for the mouse adult muscle nicotinic acetylcholine receptor.
2009-01
Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors.
2008-08
Reduced blood pressure lability during emergence from anaesthesia in rats: a pilot study using clonidine.
2008-02
Roles of amino acids and subunits in determining the inhibition of nicotinic acetylcholine receptors by competitive antagonists.
2007-06
Curariform antagonists bind in different orientations to the nicotinic receptor ligand binding domain.
2003-08-22
Curariform antagonists bind in different orientations to acetylcholine-binding protein.
2003-06-20
Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy.
1999-01
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:45:58 GMT 2025
Edited
by admin
on Mon Mar 31 17:45:58 GMT 2025
Record UNII
O0U0E87X7F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METOCURINE IODIDE
MART.   MI   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
DIMETHYLTUBOCURARINIUM IODIDE
WHO-DD  
Preferred Name English
METUBINE IODIDE
Brand Name English
METOCURINE IODIDE [MART.]
Common Name English
13H-4,6:21,24-DIETHENO-8,12-METHENO-1H-PYRIDO(3',2':14,15)(1,11)DIOXACYCLOEICOSINO(2,3,4-IJ)ISOQUINOLINIUM, 2,3,13A,14,15,16,25,25A-OCTAHYDRO-9,18,19,29-TETRAMETHOXY-1,1,14,14-TETRAMETHYL-, IODIDE (1:2), (13AR,25AS)-
Common Name English
TUBOCURARANIUM, 6,6',7',12'-TETRAMETHOXY-2,2,2',2'-TETRAMETHYL-, DIIODIDE
Common Name English
METOCURINE IODIDE [MI]
Common Name English
DIMETHYLCHONDROCURARINE IODIDE
Common Name English
(+)-O,O'-DIMETHYLCHONDROCURARINE DIIODIDE
Common Name English
NSC-36388
Code English
O,O'-DIMETHYLCHONDROCURARINE DIIODIDE
Common Name English
METOCURINE IODIDE [ORANGE BOOK]
Common Name English
Dimethyltubocurarinium iodide [WHO-DD]
Common Name English
DIMETHYL TUBOCURARINE IODIDE
Common Name English
METOCURINE IODIDE [VANDF]
Common Name English
METOCURINE IODIDE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29696
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C66131
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
MERCK INDEX
m7490
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL1259
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
PUBCHEM
24244
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
SMS_ID
100000087514
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
CAS
7601-55-0
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
FDA UNII
O0U0E87X7F
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
MESH
C032943
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
EVMPD
SUB33048
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
RXCUI
203206
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID9022944
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
ECHA (EC/EINECS)
231-510-3
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
DRUG BANK
DB00416
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
NSC
36388
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
EVMPD
SUB01752MIG
Created by admin on Mon Mar 31 17:45:58 GMT 2025 , Edited by admin on Mon Mar 31 17:45:58 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY